Correlation of Tumor-infiltrating Lymphocytes with Tumor Staging and Grading in Breast Carcinomas: A Retrospective Study

Document Type : Original Article


Department of Pathology, Hassan Institute of Medical Sciences, Karnataka, India


Background and aim: The global breast cancer mortality rate has increased by 0.23% per year globally, with a statistically significant increase in the age group under 50 and 70+. The present study evaluated Tumor-infiltrating lymphocytes(TIL) in breast carcinoma and correlated TIL with tumour stage, grade, and lymph node metastasis. 
Material and methods: A retrospective study was conducted on 66 cases of modified radical mastectomy specimens of invasive breast carcinoma. The corresponding patients' clinicopathological details like age, location, laterality, tumour size, and lymph node involvement were retried from case sheets. The histopathological reports and H&E slides were reviewed again. The representative H&E stained section of each case was selected, and TIL assessment was done based on the International TIL Working Group (ITILWG) recommendations.
Results: A total of sixty-six cases were included in our study. Out of 66 cases, the majority were seen in the age group between 51-60 years, which is 36.4%. Forty-one cases ( 62.1%) out of 66 were in size groups of 2- 5 cm. 86.4% ( 57 cases) were invasive ductal breast carcinoma. On invasive tumour lymphocyte (TIL) evaluation, grade I was noted in 22 cases, grade II in 33 cases, and 11 in grade III. 
Conclusions: Our study validates the method of histomorphological evaluation of TILs proposed by the International TIL Working Group (ITWG) 2014 in the Indian population and explores its role as a novel prognostic immune biomarker. Our analysis significantly correlated with tumour size, lymph node status, SBR grading, and histological types.


Main Subjects

[1]  Lima SM, Kehm RD, Terry MB. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinicalMedicine. 2021;38:100985.
[2]  Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia‐Pacific Journal of Clinical Oncology. 2017;13(4):289-95.
 [3] Malyguine AM, Strobl SL, Shurin MR. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunology, Immunotherapy. 2012;61:239-47.
[4]  Melichar B. Laboratory medicine and medical oncology: the tale of two Cinderellas. Clinical Chemistry and Laboratory Medicine (CCLM). 2013;51(1):99-112.
[5]  Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours. The Journal of pathology. 2014;232(2):199-209.
[6]  Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nature Reviews Cancer. 2012 Apr;12(4):298-306.
[7]  Pujani M, Jain H, Chauhan V, Agarwal C, Singh K, Singh M. Evaluation of tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage. Breast disease. 2020;39(2):61-9.
[8]  Helal TE, Ibrahim EA, Alloub AI. Immunohistochemical analysis of tumor-infiltrating lymphocytes in breast carcinoma: relation to prognostic variables. Indian Journal of Pathology and Microbiology. 2013;56(2):89.
[9]  Tsang JY, Hui SW, Ni YB, Chan SK, Yamaguchi R, Kwong A, et al. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers. Breast cancer research and treatment. 2014;143:1-9.
[10] Kolarov-Bjelobrk I, Ivkovic-Kapicl T, Jovanovic D, Trifunovic J, Radic J, Vidovic V. Clinical relevance of determination of tumour infiltrating lymphocytes in breast carcinoma. West Indian Med J. 2017. https//
[11] Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals of oncology. 2015;26(2):259-71.
[12] Rathore AS, Kumar S, Konwar R, Makker A, Negi MP, Goel MM. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. The Indian journal of medical research. 2014;140(3):361-9.
[13] Bhatia A, Kumar Y, Tumour Infiltrating Lymphocytes: Changing Trends. Clinics in Oncology. 2018;3:1409.
[14] Al-Attar A, Shehata M, Durrant L, Moseley P, Deen S, Chan S. T cell density and location can influence the prognosis of ovarian cancer. Pathology & Oncology Research. 2010;16:361-70.
[15] Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clinical Cancer Research. 2007;13(2):388-97.
[16] Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Annals of oncology. 2014;25(8):1544-50.
[17] Macchetti AH, Marana HR, Silva JS, Andrade JM, Ribeiro-Silva A, Bighetti S. Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. Clinics. 2006;61(3):203-8.
Volume 5, Issue 1
March 2023
Pages 16-20
  • Receive Date: 19 January 2023
  • Revise Date: 23 February 2023
  • Accept Date: 06 March 2023
  • First Publish Date: 12 March 2023